Axsome Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Axsome Therapeutics

18/02/2025 14:31

* Axsome Therapeutics Inc  AXSM.OQ  reported a quarterly
adjusted
loss of $1.54​​ per share for the quarter ended December 31,
higher than the same quarter last year, when the company
reported EPS of $-2.08.  The mean expectation of
seventeen analysts for the quarter was for a loss of $1.02 per
share. Wall Street expected results to range from $-1.32 to -61
cents per share.
    * Revenue rose 66% to $118.77 million from a year ago;
analysts
expected $117.64 million. 
    * Axsome Therapeutics Inc's reported EPS for the quarter was
a
loss of $1.54​.
    * The company reported a quarterly loss of $74.91 million.
    * Axsome Therapeutics Inc shares had risen by 55.0% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 7.1%
in the last three months.​ 
    * In the last 30 days, five analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 17 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Axsome
Therapeutics Inc is $151.50 
This summary was machine generated from LSEG data February 18 at
02:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2024      -1.02          -1.54          Missed
 Sep. 30 2024      -1.41          -1.34          Beat
 Jun. 30 2024      -1.33          -1.67          Missed
 Mar. 31 2024      -1.20          -1.44          Missed